Michael Murray
Professor
Pharmacology
The University of Sydney
Australia
Biography
Michael Murray graduated with a Bachelor of Pharmacy with First Class Honours and a PhD in Pharmaceutical Chemistry from the University of Sydney. After undertaking postdoctoral research with CF Wilkinson in the Institute for Comparative and Environmental Toxicology at Cornell University, Ithaca, NY he returned to Westmead Hospital and was appointed as an NHMRC Research Fellow in 1987, promoted to NHMRC Senior Research Fellow in 1989 and to NHMRC Principal Research Fellow in 1994. In 1995 he received a DSc from The University of Sydney. After 5 years at UNSW he returned in July, 2003 to the Faculty of Pharmacy at the University of Sydney before relocating to The Discipline of Pharmacology in The School of Medical Sciences in The Sydney Medical School. The Pharmacogenomics and Drug Development research laboratory is located in the Faculty's new laboratories in the Medical Foundation Building. Michael Murray is the author of 161 original papers and 37 review articles since 1982 and has presented over 70 invited seminars, workshops and symposia in Australia, North America, Singapore, Czech Republic, Germany, Thailand and the United Kingdom. He was the 2002 ASCEPT visitor to the British Toxicology Society. He has been associated with the International Society for the Study of Xenobiotics (as Councillor 1986-1989), the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (Councillor and convenor of the Drug Metabolism, Delivery and Pharmacokinetics section 2000-2003 and Deputy Chair of the Scientific Advisory Committee 2002-present) and the Gastroenterological Society of Australia (Research Advisory Committee 1989-1995). He currently serves on the editorial boards of Toxicology and Applied Pharmacology and Xenobiotica and was a recent member of the editorial boards of Current Drug Metabolism and the Journal of Gastroenterology and Hepatology.
Research Interest
Anticancer drug design and development Resistance mechanisms to anticancer drugs in human tumours Human cytochrome P450 (CYP) drug metabolism and pharmacogenetics CYP regulation by drugs, nutrients and endobiotics Adverse drug reactions caused by reactive drug metabolites Drug-drug interactions due to CYP inhibition
Publications
-
Casein Kinase 2 Is a Novel Regulator of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Trafficking.
-
Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2.
-
Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.
